{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:10Z","timestamp":1792785850782,"version":"4.5.0"},"reference-count":157,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070717"],"award-info":[{"award-number":["82070717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of Hunan Province","award":["2023JJ30950"],"award-info":[{"award-number":["2023JJ30950"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ5571"],"award-info":[{"award-number":["2024JJ5571"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Patients with end-stage renal disease (ESRD) undergoing dialysis experience higher mortality rates, increased healthcare costs, and reduced quality of life compared to those receiving allogeneic renal transplantation (RT). Although RT provides proven survival and functional benefits, long-term graft outcomes remain limited by the ongoing risk of immune-mediated rejection\u2014even in cases with donor\u2013recipient histocompatibility, except for rare syngeneic (identical twin) transplants. Additionally, the recurrence of primary autoimmune glomerular diseases, which commonly contribute to ESRD pathogenesis, continues to pose a clinical challenge for maintaining stable allograft function and optimizing long-term outcomes. While immunosuppressive therapy remains crucial to the prevention of allograft rejection and autoimmune relapse, its use is frequently associated with clinically significant complications, including nephrotoxicity, opportunistic infections, new-onset diabetes after transplantation, and an elevated risk of malignancy. Chimeric antigen receptor (CAR) regulatory T cells (Tregs) are emerging as a potential alternative to polyclonal or antigen-specific Tregs, offering advantages such as reduced cell dosing requirements and human leukocyte antigens (HLA)-independence. These features may help overcome limitations posed by HLA allele variability in genetically diverse populations. However, the concurrent use of immunosuppressive agents to prevent autoimmune relapse\u2014particularly in conditions such as focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and IgA nephropathy (IgAN)\u2014poses challenges to the therapeutic efficacy and safety profile of CAR-Tregs. Furthermore, CAR-Tregs have demonstrated potential in attenuating anti-HLA-A2 IgG donor-specific antibodies (DSAs) in na\u00efve preclinical models, their efficacy in sensitized recipients remains insufficiently established. This review explores the challenges and therapeutic potential of dual CARs and bicistronic CARs in Tregs, alongside chimeric HLA antibody receptor (CHAR) T-cell strategies, to concurrently address RT rejection and autoimmune relapse through CAR-Tregs, and allo-sensitization through CHAR-T cells. Emphasis is placed on optimizing CAR construct design, selecting appropriate target antigens, expanding eligibility criteria, and integrating CAR-Treg therapy with CHAR-T-cell-based desensitization protocols. These approaches collectively aim to improve transplant outcomes, reduce relapse rates, minimize reliance on conventional immunosuppressants, and ensure the safety and efficacy of CAR-Treg and CHAR-T cell therapies.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf248","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T11:44:22Z","timestamp":1754567062000},"source":"Crossref","is-referenced-by-count":2,"title":["Bioengineered T-cell therapies for precision immunotherapy in renal transplantation, autoimmune relapse, and sensitization"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6394-4509","authenticated-orcid":false,"given":"Amir","family":"Muhammad","sequence":"first","affiliation":[{"name":"Xiangya Hospital Central South University , Department of Nephrology, Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwei","family":"Huang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University , Department of Nephrology, Changsha, Hunan ,","place":["China"]},{"name":"Organ Fibrosis Key Lab of Hunan province, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University , Department of Nephrology, Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third Hospital of Changsha, Nephrology , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Xiangya School of Medicine, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongjing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University , Department of Nephrology, Changsha, Hunan ,","place":["China"]},{"name":"Organ Fibrosis Key Lab of Hunan province, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National International Collaborative Research Center for Medical Metabolomices , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcheng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South University , Department of Nephrology, Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"2026092306360927000_bib1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat Commun"},{"key":"2026092306360927000_bib2","doi-asserted-by":"publisher","first-page":"e167215","DOI":"10.1172\/jci.insight.167215","article-title":"Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection","volume":"8","author":"Rosado-S\u00e1nchez","year":"2023","journal-title":"JCI Insight"},{"key":"2026092306360927000_bib3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.it.2023.11.005","article-title":"Chimeric antigen receptor Treg therapy in transplantation","volume":"45","author":"Eskandari","year":"2024","journal-title":"Trends Immunol"},{"key":"2026092306360927000_bib4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11427-022-2212-5","article-title":"CARs: a new approach for the treatment of autoimmune diseases","volume":"66","author":"Sun","year":"2023","journal-title":"Sci China Life Sci"},{"key":"2026092306360927000_bib5","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1007\/s11033-022-07511-0","article-title":"Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders","volume":"49","author":"Kahmini","year":"2022","journal-title":"Mol Biol Rep"},{"key":"2026092306360927000_bib6","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele Frequency Net 2015 Update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026092306360927000_bib7","doi-asserted-by":"publisher","first-page":"874157","DOI":"10.3389\/fimmu.2022.874157","article-title":"Chimeric antigen receptor (CAR) regulatory T-cells in solid organ transplantation","volume":"13","author":"Gille","year":"2022","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of Human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"2026092306360927000_bib9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1681\/ASN.2009101093","article-title":"Recurrence of lupus nephritis after kidney transplantation","volume":"21","author":"Contreras","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026092306360927000_bib10","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","volume":"10","author":"Moroni","year":"2019","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.transproceed.2023.04.018","article-title":"Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a single-center 10-year experience","volume":"55","author":"Silva","year":"2023","journal-title":"Transplant Proc"},{"key":"2026092306360927000_bib12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092306360927000_bib13","doi-asserted-by":"publisher","first-page":"25493","DOI":"10.1038\/s41598-024-74184-z","article-title":"Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients","volume":"14","author":"Plonsky-Toder","year":"2024","journal-title":"Sci Rep"},{"key":"2026092306360927000_bib14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3324\/haematol.2015.128934","article-title":"Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells","volume":"101","author":"Scott\u00e0","year":"2016","journal-title":"Haematologica"},{"key":"2026092306360927000_bib15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"2026092306360927000_bib16","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1073\/pnas.90.15.7024","article-title":"Regression of established macroscopic liver metastases after in situ transduction of a suicide gene","volume":"90","author":"Caruso","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/jpm13121706","article-title":"Adverse drug events after kidney transplantation","volume":"13","author":"Rostaing","year":"2023","journal-title":"J Person Med"},{"key":"2026092306360927000_bib18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ekir.2022.03.030","article-title":"Study design: human leukocyte antigen class I molecule A\u221702-chimeric antigen receptor regulatory T cells in renal transplantation","volume":"7","author":"Schreeb","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026092306360927000_bib19","doi-asserted-by":"publisher","first-page":"926550","DOI":"10.3389\/fimmu.2022.926550","article-title":"Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease","volume":"13","author":"Hippen","year":"2022","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/hum.2022.183","article-title":"Efficacy and safety of dual-targeting chimeric antigen receptor-T therapy for relapsed or refractory B cell lymphoid malignancies: a systematic review and meta-analysis","volume":"34","author":"Yu","year":"2023","journal-title":"Hum Gene Ther"},{"key":"2026092306360927000_bib21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ndt\/gfae160","article-title":"Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection","volume":"40","author":"Arana","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026092306360927000_bib22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/tan.15156","article-title":"Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation","volume":"102","author":"Betriu","year":"2023","journal-title":"HLA"},{"key":"2026092306360927000_bib23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/tan.15146","article-title":"Chimeric HLA antibody receptor T cells to target HLA-specific B cells in solid organ transplantation","volume":"102","author":"Gille","year":"2023","journal-title":"HLA"},{"key":"2026092306360927000_bib24","doi-asserted-by":"publisher","first-page":"101336","DOI":"10.1016\/j.xcrm.2023.101336","article-title":"Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies","volume":"4","author":"Zhang","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026092306360927000_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2025.03.044","article-title":"The clinicopathologic characteristics of recurrent lupus nephritis post-transplant using surveillance and indication biopsies","volume":"10","author":"Suarez","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026092306360927000_bib26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12882-022-02802-x","article-title":"Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study","volume":"23","author":"J\u00e4ger","year":"2022","journal-title":"BMC Nephrol"},{"key":"2026092306360927000_bib27","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.tpr.2023.100130","article-title":"Early recurrence of focal segmental glomerulosclerosis in kidney transplant recipients: when to consider regifting","volume":"8","author":"Wood","year":"2023","journal-title":"Transplant Rep"},{"key":"2026092306360927000_bib28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/ckj\/sfac016","article-title":"Early and late ANCA vasculitis relapses after kidney transplantation may have different presentations","volume":"15","author":"Masset","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026092306360927000_bib29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"2026092306360927000_bib30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/TP.0000000000002049","article-title":"The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis","volume":"102","author":"Wan","year":"2018","journal-title":"Transplantation"},{"key":"2026092306360927000_bib31","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat Commun"},{"key":"2026092306360927000_bib32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of Bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026092306360927000_bib33","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"key":"2026092306360927000_bib34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026092306360927000_bib35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ajt.2022.11.001","article-title":"Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy","volume":"23","author":"Hill","year":"2023","journal-title":"Am J Transplant"},{"key":"2026092306360927000_bib36","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026092306360927000_bib37","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"2026092306360927000_bib38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gendis.2021.07.001","article-title":"Anti-C4d chimeric antigen receptor regulatory T cells suppressed allograft rejection in ABO-incompatible heart transplantation","volume":"9","author":"Lee","year":"2022","journal-title":"Genes Disease"},{"key":"2026092306360927000_bib39","doi-asserted-by":"publisher","first-page":"100614","DOI":"10.1016\/j.xcrm.2022.100614","article-title":"Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque","volume":"3","author":"Ellis","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026092306360927000_bib40","doi-asserted-by":"publisher","first-page":"686439","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib41","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/ajt.15787","article-title":"Donor-specific chimeric antigen receptor tregs limit rejection in naive but not sensitized allograft recipients","volume":"20","author":"Sicard","year":"2020","journal-title":"Am J Transplant"},{"key":"2026092306360927000_bib42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","volume":"30","author":"Proics","year":"2023","journal-title":"Gene Ther"},{"key":"2026092306360927000_bib43","doi-asserted-by":"publisher","first-page":"e123672","DOI":"10.1172\/jci.insight.123672","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI Insight"},{"key":"2026092306360927000_bib44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"2026092306360927000_bib45","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1182\/bloodadvances.2019000411","article-title":"Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice","volume":"3","author":"B\u00e9zie","year":"2019","journal-title":"Blood Adv"},{"key":"2026092306360927000_bib46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41231-023-00150-y","article-title":"Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease","volume":"8","author":"Bastian","year":"2023","journal-title":"Transl Med Commun"},{"key":"2026092306360927000_bib47","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"2026092306360927000_bib48","doi-asserted-by":"publisher","first-page":"e168601","DOI":"10.1172\/JCI168601","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"2026092306360927000_bib49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092306360927000_bib50","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092306360927000_bib51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092306360927000_bib52","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026092306360927000_bib53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41581-023-00714-z","article-title":"HLA class II expression levels and alloimmune risk","volume":"19","author":"Wang","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026092306360927000_bib54","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMed"},{"key":"2026092306360927000_bib55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaut.2018.02.006","article-title":"Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology","volume":"90","author":"Koristka","year":"2018","journal-title":"J Autoimmun"},{"key":"2026092306360927000_bib56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother"},{"key":"2026092306360927000_bib57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2026092306360927000_bib58","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"2026092306360927000_bib59","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"2026092306360927000_bib60","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2026092306360927000_bib61","doi-asserted-by":"publisher","first-page":"639818","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib62","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"2026092306360927000_bib63","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"2026092306360927000_bib64","doi-asserted-by":"publisher","first-page":"eaaz3866","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026092306360927000_bib65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2026092306360927000_bib66","doi-asserted-by":"publisher","first-page":"e126194","DOI":"10.1172\/jci.insight.126194","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function","volume":"4","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"key":"2026092306360927000_bib67","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib68","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation\u201d","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol Ther"},{"key":"2026092306360927000_bib69","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"2026092306360927000_bib70","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"2026092306360927000_bib71","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","article-title":"Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions","volume":"30","author":"Lam","year":"2023","journal-title":"Mol Ther Oncolytic"},{"key":"2026092306360927000_bib72","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41467-019-10097-0","article-title":"Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response","volume":"10","author":"Baeuerle","year":"2019","journal-title":"Nat Commun"},{"key":"2026092306360927000_bib73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/BTT.S291768","article-title":"Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biol Targets Ther"},{"key":"2026092306360927000_bib74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"2026092306360927000_bib75","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.7150\/ijbs.108036","article-title":"From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"2026092306360927000_bib76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-018-0083-6","article-title":"Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation","volume":"19","author":"Klein","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2026092306360927000_bib77","doi-asserted-by":"publisher","first-page":"e1612","DOI":"10.1371\/journal.pone.0001612","article-title":"FOXP3 promoter demethylation reveals the committed Treg population in humans","volume":"3","author":"Janson","year":"2008","journal-title":"PLoS ONE"},{"key":"2026092306360927000_bib78","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/eji.200838105","article-title":"DNA methylation controls Foxp3 gene expression","volume":"38","author":"Polansky","year":"2008","journal-title":"Eur J Immunol"},{"key":"2026092306360927000_bib79","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1073\/pnas.0900621106","article-title":"Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t","volume":"106","author":"Ayyoub","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib80","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.jaut.2022.102986","article-title":"Engineered treg cells: the heir to the throne of immunotherapy","volume":"144","author":"Stucchi","year":"2024","journal-title":"J Autoimmun"},{"key":"2026092306360927000_bib81","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.jaut.2023.103057","article-title":"Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","volume":"138","author":"Henschel","year":"2023","journal-title":"J Autoimmun"},{"key":"2026092306360927000_bib82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"2026092306360927000_bib83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jcyt.2020.10.002","article-title":"HLA-A*02:01-directed Chimeric Antigen Receptor\/Forkhead Box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease","volume":"23","author":"Martin","year":"2021","journal-title":"Cytotherapy"},{"key":"2026092306360927000_bib84","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"2026092306360927000_bib85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral vectors for gene therapy: translational and clinical outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"key":"2026092306360927000_bib86","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"2026092306360927000_bib87","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1073\/pnas.83.10.3194","article-title":"Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells","volume":"83","author":"Yu","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib88","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/hum.2012.203","article-title":"Mechanisms of retroviral integration and mutagenesis","volume":"24","author":"Cavazza","year":"2013","journal-title":"Hum Gene Ther"},{"key":"2026092306360927000_bib89","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"2026092306360927000_bib90","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"2026092306360927000_bib91","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"2026092306360927000_bib92","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2026092306360927000_bib93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","article-title":"Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects","volume":"56","author":"Poorebrahim","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026092306360927000_bib94","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1126\/science.1091667","article-title":"Gene therapy insertional mutagenesis insights","volume":"303","author":"Dav\u00e9","year":"2004","journal-title":"Science"},{"key":"2026092306360927000_bib95","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.iotech.2023.100375","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immuno-Oncol Technol"},{"key":"2026092306360927000_bib96","doi-asserted-by":"publisher","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","article-title":"The past, present, and future of non-viral CAR T cells","volume":"13","author":"Moretti","year":"2022","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib97","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of advanced leukemia in mice with mRNA engineered T cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Hum Gene Ther"},{"key":"2026092306360927000_bib98","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3390\/cells9061337","article-title":"Transposon-based CAR T cells in acute leukemias: where are we going?","volume":"9","author":"Magnani","year":"2020","journal-title":"Cells"},{"key":"2026092306360927000_bib99","doi-asserted-by":"publisher","first-page":"114961","DOI":"10.1016\/j.addr.2023.114961","article-title":"Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics","volume":"199","author":"Kang","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"2026092306360927000_bib100","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.3390\/ijms22105084","article-title":"Contemporary transposon tools: a review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering","volume":"22","author":"Sandoval-Villegas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026092306360927000_bib101","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"2026092306360927000_bib102","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","article-title":"Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res"},{"key":"2026092306360927000_bib103","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/gt.2009.144","article-title":"Extending the transposable payload limit of Sleeping Beauty (SB) using the herpes simplex virus (HSV)\/SB amplicon-vector platform","volume":"17","author":"de Silva","year":"2010","journal-title":"Gene Ther"},{"key":"2026092306360927000_bib104","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s10147-023-02319-9","article-title":"piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies","volume":"28","author":"Yagyu","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2026092306360927000_bib105","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026092306360927000_bib106","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Molecular Ther Meth Clin Develop"},{"key":"2026092306360927000_bib107","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","article-title":"Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026092306360927000_bib108","doi-asserted-by":"publisher","first-page":"51581","DOI":"10.18632\/oncotarget.9955","article-title":"Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform","volume":"7","author":"Magnani","year":"2016","journal-title":"Oncotarget"},{"key":"2026092306360927000_bib109","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol"},{"key":"2026092306360927000_bib110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat Rev Mater"},{"key":"2026092306360927000_bib111","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1039\/d1lc00219h","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"key":"2026092306360927000_bib112","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41551-023-01073-7","article-title":"Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway","volume":"8","author":"An","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"2026092306360927000_bib113","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"2026092306360927000_bib114","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jcyt.2023.01.005","article-title":"Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering","volume":"25","author":"Si","year":"2023","journal-title":"Cytotherapy"},{"key":"2026092306360927000_bib115","doi-asserted-by":"publisher","first-page":"e2303215","DOI":"10.1002\/advs.202303215","article-title":"Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci"},{"key":"2026092306360927000_bib116","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett"},{"key":"2026092306360927000_bib117","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","article-title":"In vitro engineering chimeric antigen receptor macrophages and T cells by lipid nanoparticle-mediated mRNA delivery","volume":"8","author":"Ye","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"2026092306360927000_bib118","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1093\/hmg\/ddu125","article-title":"CRISPR\/Cas9 for genome editing: progress, implications and challenges","volume":"23","author":"Zhang","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2026092306360927000_bib119","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"2026092306360927000_bib120","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"2026092306360927000_bib121","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","article-title":"Simultaneous deletion of endogenous tcr\u03b1\u03b2 for TCR gene therapy creates an improved and safe cellular therapeutic","volume":"28","author":"Morton","year":"2020","journal-title":"Mol Ther"},{"key":"2026092306360927000_bib122","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/ni.3004","article-title":"Continuous requirement for the TCR in regulatory T cell function","volume":"15","author":"Levine","year":"2014","journal-title":"Nat Immunol"},{"key":"2026092306360927000_bib123","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","article-title":"CRISPR-Cas9 for cancer therapy: opportunities and challenges","volume":"447","author":"Chen","year":"2019","journal-title":"Cancer Lett"},{"key":"2026092306360927000_bib124","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2026092306360927000_bib125","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"2026092306360927000_bib126","doi-asserted-by":"publisher","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","article-title":"Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria","volume":"109","author":"Gasiunas","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib127","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of Systemic Lupus Erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"2026092306360927000_bib128","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026092306360927000_bib129","doi-asserted-by":"publisher","first-page":"1465191","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib130","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.tmrv.2020.09.004","article-title":"Fetal and neonatal alloimmune thrombocytopenia-new prospects for Fetal risk assessment of HPA-1a-negative pregnant women","volume":"34","author":"Kjeldsen-Kragh","year":"2020","journal-title":"Transfus Med Rev"},{"key":"2026092306360927000_bib131","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.it.2018.01.008","article-title":"The impact of sex on alloimmunity","volume":"39","author":"Lau","year":"2018","journal-title":"Trends Immunol"},{"key":"2026092306360927000_bib132","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-4939-2690-9_10","article-title":"Next-generation sequencing for antenatal prediction of KEL1 blood group status","volume":"1310","author":"Rieneck","year":"2015","journal-title":"Methods Mol Biol"},{"key":"2026092306360927000_bib133","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026092306360927000_bib134","article-title":"Depletion of alloreactive B cells by chimeric alloantigen receptor T cells with drug resistance to prevent antibody-mediated rejection in solid organ transplantation","author":"Dragon","year":"2023","journal-title":"Biorxiv"},{"key":"2026092306360927000_bib135","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1038\/ncomms13600","article-title":"Mature IgM-expressing plasma cells sense antigen and develop competence for cytokine production upon antigenic challenge","volume":"7","author":"Blanc","year":"2016","journal-title":"Nat Commun"},{"key":"2026092306360927000_bib136","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1182\/blood-2012-09-459289","article-title":"A functional BCR in human IgA and IgM plasma cells","volume":"121","author":"Pinto","year":"2013","journal-title":"Blood"},{"key":"2026092306360927000_bib137","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-023-01799-7","article-title":"Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing","volume":"22","author":"Balke-Want","year":"2023","journal-title":"Mol Cancer"},{"key":"2026092306360927000_bib138","doi-asserted-by":"publisher","first-page":"eabc3791","DOI":"10.1126\/sciadv.abc3791","article-title":"Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking","volume":"7","author":"Kelly","year":"2021","journal-title":"Sci Adv"},{"key":"2026092306360927000_bib139","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/ijms23031689","article-title":"Challenges of CRISPR-based gene editing in primary T cells","volume":"23","author":"Rezalotfi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026092306360927000_bib140","doi-asserted-by":"publisher","first-page":"e2219086120","DOI":"10.1073\/pnas.2219086120","article-title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","volume":"120","author":"Lamarche","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib141","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"2026092306360927000_bib142","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1038\/s41467-021-26844-1","article-title":"Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction","volume":"12","author":"Lamarth\u00e9e","year":"2021","journal-title":"Nat Commun"},{"key":"2026092306360927000_bib143","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"2026092306360927000_bib144","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/eji.202048934","article-title":"Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive","volume":"51","author":"Mohseni","year":"2021","journal-title":"Eur J Immunol"},{"key":"2026092306360927000_bib145","doi-asserted-by":"publisher","first-page":"19954","DOI":"10.1073\/pnas.0704397104","article-title":"Allograft rejection mediated by memory T cells is resistant to regulation","volume":"104","author":"Yang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092306360927000_bib146","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026092306360927000_bib147","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.humimm.2020.06.004","article-title":"Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for deceased donor expedited HLA typing","volume":"81","author":"Mosbruger","year":"2020","journal-title":"Hum Immunol"},{"key":"2026092306360927000_bib148","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/tan.13926","article-title":"Rapid, highly accurate and cost-effective open-source simultaneous complete HLA typing and phasing of class I and II alleles using nanopore sequencing","volume":"96","author":"Stockton","year":"2020","journal-title":"HLA"},{"key":"2026092306360927000_bib149","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.humimm.2021.01.010","article-title":"New challenges, new opportunities: next generation sequencing and its place in the advancement of HLA typing","volume":"82","author":"Bravo-Egana","year":"2021","journal-title":"Hum Immunol"},{"key":"2026092306360927000_bib150","doi-asserted-by":"publisher","first-page":"1163633","DOI":"10.3389\/fimmu.2023.1163633","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib151","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3389\/fimmu.2017.00727","article-title":"What else can CD39 tell us?","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib152","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/cells11111844","article-title":"Differential expression of CD45RO and CD45RA in bovine T cells","volume":"11","author":"Kandel","year":"2022","journal-title":"Cells"},{"key":"2026092306360927000_bib153","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/TP.0000000000004316","article-title":"Do Treg speed up with CARs? Chimeric antigen receptor Treg engineered to induce transplant tolerance","volume":"107","author":"Kaljanac","year":"2023","journal-title":"Transplantation"},{"key":"2026092306360927000_bib154","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3389\/fimmu.2020.01608","article-title":"The future of regulatory T cell therapy: promises and challenges of implementing CAR technology","volume":"11","author":"Mohseni","year":"2020","journal-title":"Front Immunol"},{"key":"2026092306360927000_bib155","doi-asserted-by":"publisher","first-page":"103341","DOI":"10.1016\/j.msard.2021.103341","article-title":"Inducing chimeric antigen receptor (CAR) regulatory T cells in-vivo: a novel concept for a potential feasible cure of demyelinating diseases","volume":"57","author":"Sedaghat","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2026092306360927000_bib156","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1681\/ASN.2020010019","article-title":"Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study","volume":"31","author":"Senev","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026092306360927000_bib157","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1172\/JCI87993","article-title":"Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue","volume":"127","author":"Vallabhajosyula","year":"2017","journal-title":"J Clin Invest"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf248\/63991526\/sfaf248.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/9\/sfaf248\/63991526\/sfaf248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/9\/sfaf248\/63991526\/sfaf248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:36:18Z","timestamp":1790159778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf248\/8228477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":157,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf248","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,8]]},"article-number":"sfaf248"}}